What is GlycoMimetics?
GlycoMimetics operates at the intersection of advanced biochemistry and clinical medicine, focusing on the development of glycomimetic drugs. By targeting selectins and other carbohydrate-binding proteins, the company aims to modulate biological pathways involved in disease progression. Its lead product candidates, such as rivipansel and GMI-1271, represent a sophisticated portfolio designed to treat debilitating conditions like vaso-occlusive crisis and acute myeloid leukemia. The company's strategic research and development agreement with industry leaders like Pfizer Inc. further validates its scientific methodology and market position within the competitive biopharmaceutical landscape.
How much funding has GlycoMimetics raised?
GlycoMimetics has raised a total of $288.8M across 7 funding rounds:
Series A
$9.6M
Series B
$15.4M
Series C
$38M
Stock Offering
$57.4M
Corporate Investment
$20M
Stock Offering
$20M
Stock Offering
$128.4M
Series A (2004): $9.6M with participation from New Enterprise Associates, Anthem Capital Management, PTV Sciences, Alliance Technology Ventures, Novartis Venture Fund, and Maryland Department of Business and Economic Development
Series B (2006): $15.4M led by Novartis Venture Fund, Anthem Capital Management, PTV Sciences, Alliance Technology Ventures, Maryland Department of Business and Economic Development, and New Enterprise Associates
Series C (2009): $38M supported by Genzyme Ventures, Alliance Technology Ventures, Novartis Venture Fund, Anthem Capital, and New Enterprise Associates
Stock Issuance/Offering (2014): $57.4M featuring Undisclosed
Corporate Investment (2015): $20M backed by Pfizer Inc.
Stock Issuance/Offering (2016): $20M with participation from Undisclosed
Stock Issuance/Offering (2018): $128.4M led by Undisclosed
Key Investors in GlycoMimetics
New Enterprise Associates
Established in 1977 and headquartered in Menlo Park, California, New Enterprise Associates is a prominent venture capital firm focused on helping entrepreneurs build transformative businesses.
Novartis Venture Fund
Novartis is a global pharmaceutical manufacturer specializing in the research and development of innovative medications across multiple therapeutic areas to improve patient outcomes worldwide.
Alliance Technology Ventures
Alliance Technology Ventures is a venture capital firm focused on private company investments in the life science and communication sectors, providing both financial support and hands-on guidance.
What's next for GlycoMimetics?
Looking ahead, GlycoMimetics is positioned to leverage its historical capital base to drive its late-stage clinical programs toward potential commercialization. The firm's focus remains on the rigorous execution of Phase III trials and the expansion of its pipeline, which includes GMI-1359 and various galectin inhibitors. As the company continues to refine its therapeutic candidates, the strategic deployment of its recent financing will be critical in maintaining its competitive edge. Future growth will likely hinge on successful regulatory milestones and the continued validation of its glycomimetic platform in addressing high-acuity medical challenges.
See full GlycoMimetics company page
